■ Analysis · July 18, 2026
Pfizer's $14.6B Dividend Payout Faces Patent Cliff Risks
Pfizer paid $14.6 billion in dividends over 18 months, but upcoming patent expirations on key drugs and a high payout ratio raise questions about dividend sustainability.
Dividend Payouts and Financial Health
Over the last six quarters, Pfizer (NYSE: PFE) has distributed $14.6 billion in dividends to shareholders. In 2025, the company paid roughly $9.8 billion, and in the first half of 2026, it paid approximately $4.8 billion. The trailing 12-month dividend payout ratio stood at over 130% at the end of the first quarter of 2026 based on earnings. However, when measured against cash flow, the cash dividend payout ratio was a more reassuring 103%.
Pfizer ended the first quarter of 2026 with $1.7 billion in cash and $11.3 billion in short-term investments, providing a cushion to sustain dividends for several quarters. The company also has the option to take on additional debt to support payouts. Management has explicitly stated that maintaining the dividend is a key long-term goal, as noted in the first-quarter slide deck.
Patent Cliff Challenges
Pfizer faces a significant patent cliff in the coming years. Oncology drug Ibrance is set to lose patent protection in 2027, followed by cardiovascular drugs Eliquis and Vyndaqel in 2028. These drugs represent major revenue streams, and the company currently lacks large new drugs ready to offset the expected revenue declines from generic competition. Additionally, Pfizer experienced a setback in 2025 when it discontinued a GLP-1 drug candidate, though it later acquired a company with a more promising candidate in that space.
Dividend Sustainability Outlook
The high dividend yield—around 7% compared to the S&P 500's 1% and the pharmaceutical sector average of 1.5%—reflects investor concerns about dividend safety. While the board of directors has discretion over dividend payments, the company's long history and ability to pivot suggest it may navigate the patent cliff. A worst-case scenario could involve a 50% dividend reduction, which would still leave an above-average yield and may already be priced into the stock.
What it means for income investors
Pfizer's dividend faces headwinds from upcoming patent expirations and a high payout ratio, but the company has financial flexibility and management commitment to the dividend. The risk of a cut is real, but the potential reward for those willing to accept that risk could be significant given the current yield.
Reporting based on: Yahoo Finance. Figures verified against market data where available.